1426055-76-6

Basic information

• Product Name: 4-[3-(4-nitrophenyl)propyl]-1,3-thiazol-2-amine
• Synonyms: 4-[3-(4-nitrophenyl)propyl]-1,3-thiazol-2-amine
• CAS NO: 1426055-76-6
• Molecular Weight: 263.32
• Mol File: 1426055-76-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[3-(4-nitrophenyl)propyl]-1,3-thiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(4-nitrophenyl)propyl]-1,3-thiazol-2-amine(1426055-76-6)
• EPA Substance Registry System: 4-[3-(4-nitrophenyl)propyl]-1,3-thiazol-2-amine(1426055-76-6)

Safety Data

• Hazardous Substances Data: 1426055-76-6(Hazardous Substances Data)

Upstream product

• 103454-18-8 5-(4-nitrophenyl)pentan-2-one 
• 17356-08-0 thiourea 

Downstream Products

• 874900-79-5 N-{4-[3-(4-aminophenyl)propyl]-1,3-thiazol-2-yl}acetamide 
• 874964-40-6 di-tert-butyl {(Z)-[(4-{3-[2-(acetylamino)-1,3-thiazol-4-yl]propyl}phenyl)amino]methylidene}biscarbamate 
• 183365-27-7 N-{4-[3-(4-nitrophenyl)propyl]-1,3-thiazol-2-yl}acetamide 

Relevant articles and documents

Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema

Vascular adhesion protein-1 (VAP-1), an amine oxidase that is also known as a semicarbazide-sensitive amine oxidase (SSAO), is present in particularly high levels in human plasma, and is considered a potential therapeutic target for various inflammatory diseases, including diabetes complications such as macular edema. In our VAP-1 inhibitor program, structural modifications following high-throughput screening (HTS) of our compound library resulted in the discovery that thiazole derivative 10, which includes a guanidine group, shows potent human VAP-1 inhibitory activity (IC50 of 230 nM; rat IC 50 of 14 nM). Moreover, compound 10 exhibited significant inhibitory effects on ocular permeability in STZ-induced diabetic rats.